Drug Profile
BPRx 060216
Alternative Names: BPRx-060216Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Biotica Pharmaceuticals
- Class Anti-inflammatories; Cannabinoids
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Eosinophilic oesophagitis
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for preclinical development in Eosinophilic-oesophagitis in USA
- 03 Aug 2016 Preclinical trials in Eosinophilic oesophagitis in USA (unspecified route)
- 03 Aug 2016 Biotica files for patent protection for BPRx™ technology (Biotica website, August 2016) before August 2016